Enanta Pharmaceuticals (ENTA) Cash from Investing Activities Growth (5y) (2017 - 2026)

Enanta Pharmaceuticals (ENTA) Cash from Investing Activities Growth (5y) (2017 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Enanta Pharmaceuticals 369.97 Mn 206.20 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -14.05%
Dec 31, 2025 -22.08%
Sep 30, 2025 -1.72%
Jun 30, 2025 -24.48%
Mar 31, 2025 -16.62%
Dec 31, 2024 30.96%
Sep 30, 2024 18.79%
Jun 30, 2024 15.64%
Mar 31, 2024 113.49%
Dec 31, 2023 8.92%
Sep 30, 2023 28.39%
Jun 30, 2023 -35.88%
Mar 31, 2023 48.59%
Dec 31, 2022 73.48%
Sep 30, 2022 31.25%
Jun 30, 2022 16.19%
Mar 31, 2022 -84.55%
Dec 31, 2021 120.90%
Sep 30, 2021 69.09%
Jun 30, 2021 -6.82%